An interventional study of Unipolar QS-Potential Guided Catheter Ablation and Conventional Pulmonary Vein Isolation in Atrial Fibrillation (AF), sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases — 19 open to participants now, 19 under way, none of them phase 3. Atrial Fibrillation · China National Center for Cardiovascular Diseases.
Among the 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2026, is one of 16 with no phase, reaches primary completion later than 7 of the 18 other live ones, and was the 22nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →19 of the 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases are open now, in 2 countries. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–85
China National Center for Cardiovascular Diseases · Sites in United States, China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 283 across the 20 interventional studies, 265 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
5 of the studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06108414China National Center for Cardiovascular DiseasesLow-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation | 2026-12-31 |
| NCT07146061China National Center for Cardiovascular DiseasespCAD-POAF 3 Year Follow-up | 2027-01 |
| NCT07572253China National Center for Cardiovascular DiseasesA Study of Using CARTO SOUND™ FAM to Guide Pulsed Field Ablation for Atrial Fibrillation | 2027-06-01 |
| NCT07927582China National Center for Cardiovascular DiseasesPulsed Field Ablation for Atrial Fibrillation Under General Anesthesia Versus Remimazolam-based Deep Sedation | 2027-11-30 |
| NCT07601763China National Center for Cardiovascular DiseasesPulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF) | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial fibrillation (AF) is a common heart rhythm disorder. While catheter ablation is an effective treatment, many patients still experience AF recurrence after the procedure. One major reason is that the mechanisms that maintain AF are not fully understood. Research suggests that the outer layer of the heart (epicardium) may play an important role in keeping AF going. However, current mapping techniques have limitations in detecting electrical signals from both the inner and outer heart layers.
This study uses a different technique called unipolar voltage mapping, which may more accurately capture electrical signals from both heart layers. Specifically, we focus on a specific type of electrical signal called "QS potential" on unipolar mapping, which reflects breakthrough sites between the inner and outer heart layers.
In this interventional study, participants with AF undergoing catheter ablation will receive personalized ablation guided by unipolar QS-potential mapping. We aim to:
Explore the relationship between unipolar QS-potentials and AF maintenance and atrial remodeling Evaluate the effectiveness of QS-potential guided personalized AF ablation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm undergo catheter ablation for atrial fibrillation guided by unipolar QS-potential mapping. Ablation is delivered to these identified target sites in addition to standard pulmonary vein isolation.
Procedure: Unipolar QS-Potential Guided Catheter Ablation
Participants in this arm undergo conventional pulmonary vein isolation for atrial fibrillation using standard bipolar voltage mapping. Ablation is performed to achieve electrical isolation of the pulmonary veins, without additional mapping-guided ablation beyond PVI.
Procedure: Conventional Pulmonary Vein Isolation
Participants in this arm undergo catheter ablation for atrial fibrillation guided by unipolar QS-potential mapping. Intracardiac unipolar voltage mapping is performed to identify QS-potentials, which reflect epicardial-endocardial breakthrough sites. Ablation is delivered to these identified target sites in addition to standard pulmonary vein isolation.
Participants in this arm undergo conventional pulmonary vein isolation for atrial fibrillation using standard bipolar voltage mapping. Ablation is performed to achieve electrical isolation of the pulmonary veins, without additional mapping-guided ablation beyond PVI.
Freedom from Atrial Fibrillation Recurrence at 3 Months Post Ablation
Freedom from any episode of atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) lasting ≥30 seconds, as detected by electrocardiogram (ECG) or 24-hour Holter monitoring, after a 3-month blanking period following the ablation procedure.
Time frame: 3 months (from month 1 to month 6 post-ablation)
Total ablation time
Total duration of radiofrequency energy delivery during the ablation procedure, measured in minutes. This includes all ablation applications (both pulmonary vein isolation and additional lesion sets) from the first to the last energy application.
Time frame: Intraoperative (on the day of the ablation procedure)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Sep 2026, 2 months later.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 2 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →